Topiramate oral suspension - OWP Pharmaceuticals
Alternative Names: Topiramate liquid oral suspension - OWP PharmaceuticalsLatest Information Update: 12 Jul 2023
At a glance
- Originator OWP Pharmaceuticals
- Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
- Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Epilepsy; Migraine
Most Recent Events
- 12 Jul 2023 Clinical trials in Epilepsy in USA (PO) (OWP Pharmaceuticals pipeline, July 2023)
- 12 Jul 2023 Clinical trials in Migraine in USA (PO) (OWP Pharmaceuticals pipeline, July 2023)
- 05 Dec 2019 Chemical structure information added